TG Therapeutics (NASDAQ:TGTX) Stock Crosses Above Two Hundred Day Moving Average of $6.83

TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.83 and traded as high as $6.86. TG Therapeutics shares last traded at $6.59, with a volume of 1,447,417 shares trading hands.

Analysts Set New Price Targets

TGTX has been the topic of a number of recent analyst reports. raised TG Therapeutics to a “sell” rating in a research report on Friday, June 17th. B. Riley reduced their price target on shares of TG Therapeutics from $23.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 13th. Three investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to, the company presently has an average rating of “Hold” and a consensus price target of $21.25.

TG Therapeutics Trading Down 2.1 %

The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 0.53. The stock has a market cap of $957.36 million, a PE ratio of -3.05 and a beta of 2.19. The business’s fifty day moving average is $6.83 and its 200 day moving average is $6.83.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TGTX. Eagle Asset Management Inc. increased its stake in TG Therapeutics by 5.0% during the 1st quarter. Eagle Asset Management Inc. now owns 475,190 shares of the biopharmaceutical company’s stock worth $4,519,000 after buying an additional 22,837 shares during the period. Ensign Peak Advisors Inc purchased a new position in TG Therapeutics during the fourth quarter valued at approximately $599,000. Geode Capital Management LLC grew its position in TG Therapeutics by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,309,837 shares of the biopharmaceutical company’s stock valued at $43,886,000 after purchasing an additional 7,459 shares in the last quarter. Duality Advisers LP bought a new stake in TG Therapeutics in the first quarter worth approximately $994,000. Finally, Lion Point Capital LP grew its position in TG Therapeutics by 38.3% in the fourth quarter. Lion Point Capital LP now owns 1,160,307 shares of the biopharmaceutical company’s stock worth $22,045,000 after acquiring an additional 321,179 shares in the last quarter. Institutional investors and hedge funds own 72.64% of the company’s stock.

About TG Therapeutics

(Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

Featured Articles

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with's FREE daily email newsletter.